Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Aging (Upcoming)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • Gut-Brain Axis (Jul 2021)
    • Tumor Microenvironment (Mar 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Regulated formation of eicosanoids
F.A. Fitzpatrick, Roy Soberman
F.A. Fitzpatrick, Roy Soberman
Published June 1, 2001
Citation Information: J Clin Invest. 2001;107(11):1347-1351. https://doi.org/10.1172/JCI13241.
View: Text | PDF
Perspective

Regulated formation of eicosanoids

  • Text
  • PDF
Abstract

Authors

F.A. Fitzpatrick, Roy Soberman

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Stages of eicosanoid biosynthesis. Under basal conditions, release and m...
Stages of eicosanoid biosynthesis. Under basal conditions, release and metabolism of arachidonic acid (AA) are balanced, leaving little AA available as a substrate for COXs, so little prostaglandin E2 is formed. With the breaching (lightning bolts) of two successive metabolic thresholds, two additional phospholipases are activated, permitting the accumulation of AA and the formation of its downstream metabolites. Prior to stimulation, the cycle shown in red predominates, wherein membrane phospholipids are hydrolyzed by the phospholipase A2 isoform iPLA2, yielding low quantities of AA that are recycled by the action of acylases to reform membrane phospholipid. However, following growth factor receptor activation, Ca2+ levels rise and the inducible phospholipase cPLA2 (shown in blue) begins to generate sufficient AA that COX-1 and, later, COX-2 become active. COX-1 activity is coupled to a cytosolic form of the PGH-PGE isomerase, whereas COX-2 is coupled to a membrane-bound form of the enzyme. Following prolonged receptor occupancy and activation, yet another phospholipase, sPLA2 (shown in green), is induced. This enzyme is secreted and can therefore activate prostaglandin synthesis in neighboring cells by a paracrine mechanism.

Copyright © 2022 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts